ArticlePloS one2020

Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma.

Sakura Kirino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.